HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year ended December 31, 2014.
2014 OPERATIONAL AND FINANCIAL HIGHLIGHTS
•2014 Operational Highlights
?In the fourth quarter of 2014, Bio-Path successfully completed Cohort 6 of its Phase 1 clinical trial evaluating its lead compound, Liposomal Grb-2, in blood cancers.
Help employers find you! Check out all the jobs and post your resume.
